 impact. But the main point is that our cash flow conversion is due to the asset-light business model we have, and the software acquisitions have really driven this incredible increase in cash flow to revenue ratios. So, to summarize, based on the insights from the recent earnings conference call transcript, the company has achieved record results in orders, revenue, net earnings, EBITDA, and cash flow. The segment outlook shows positive organic growth in all four segments, with particular growth in the Medical and RF Technology segments. The company has made transformational acquisitions in the software end markets and professional services, diversifying its business and contributing to strong cash flow performance. The guidance for 2017 includes adjusted earnings of $8.82 to $9.22 per share, representing 20% to 22% revenue growth, with a 3% to 5% organic growth. Operating cash flow is expected to reach $1.150 billion, a 15% increase from the previous year. Overall, the company is well-positioned for 2017 with broad-based opportunities, optimistic end markets, and strong momentum for growth. As a financial analyst, adopting an 'overweight' investment stance, I recommend an investment in the company, with confidence in its strong financial performance and outlook for the future.